Most retinoblastoma survivors have normal psychosocial functioning
the ONA take:
Most retinoblastoma survivors do not have poorer psychosocial functioning compared with people without cancer, a recent study published online ahead of print in the Journal of Clinical Oncology has shown.
Although survival rates for patients with retinoblastoma are higher than 95% in the United States, there is limited data about the long-term psychosocial outcomes of these survivors.
For the study, researchers surveyed 470 retinoblastoma survivors diagnosed between 1932 and 1994 and treated in New York. Of those, 53.6% had retinoblastoma in both eyes.
Participants completed a comprehensive questionnaire by mail or telephone to evaluate psychosocial outcomes such as psychological distress, anxiety, depression, fear of cancer recurrence, satisfaction with facial appearance, and post-traumatic stress symptoms.
Results showed that retinoblastoma survivors did not have significantly higher rates of depression, somatization, distress, or anxiety compared with noncancer controls.
Researchers also found that bilateral and unilateral retinoblastoma survivors have similar psychological symptoms.
According to the American Cancer Society, retinoblastoma is a rare disease diagnosed in only approximately 200 to 300 children each year in the United States.
Most retinoblastoma survivors do not have poorer psychosocial functioning compared with people without cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|